Vera Therapeutics Inc (VERA)
41.94
-0.75
(-1.76%)
USD |
NASDAQ |
May 16, 16:00
42.95
+1.01
(+2.41%)
After-Hours: 20:00
Vera Therapeutics Cash from Operations (TTM): -99.72M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -99.72M |
| December 31, 2023 | -92.18M |
| September 30, 2023 | -88.20M |
| June 30, 2023 | -83.65M |
| March 31, 2023 | -84.91M |
| December 31, 2022 | -67.60M |
| September 30, 2022 | -52.87M |
| Date | Value |
|---|---|
| June 30, 2022 | -39.94M |
| March 31, 2022 | -28.57M |
| December 31, 2021 | -23.71M |
| September 30, 2021 | -44.65M |
| June 30, 2021 | -41.62M |
| March 31, 2021 | -36.62M |
| December 31, 2020 | -34.81M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-99.72M
Minimum
Mar 2024
-23.71M
Maximum
Dec 2021
-58.50M
Average
-48.76M
Median
Cash from Operations (TTM) Benchmarks
| Vertex Pharmaceuticals Inc | 3.944B |
| Alpine Immune Sciences Inc | -80.55M |
| Fate Therapeutics Inc | -136.75M |
| Mersana Therapeutics Inc | -172.53M |
| Equillium Inc | -22.59M |